Pune, India, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The global breast cancer therapeutics market is set to gain impetus from the ongoing research and developments to come up with state-of-the-art drugs. The study further mentions that the breast cancer therapeutics market size was USD 21.58 billion in 2019 and is projected to reach USD 55.27 billion by 2027, exhibiting a CAGR of 13.1% during the forecast period.
This information is given by Fortune Business Insights™ in a new study, titled, "Breast Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, and Immunotherapy), By Cancer Type (Hormone Receptor, and HER2+), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2020-2027."
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/breast-cancer-therapeutics-market-100163
Industry Development
- September 2020 – Natco Pharma announced that its marketing partner, Lupin, launched Lapatinib Tablets, 250 mg, in the U.S. after Natco received the final approval for its Abbreviated New Drug Application (ANDA) from the U.S. Federal Drug Administration (USFDA). NATCO was the first ANDA applicant for Lapatinib Tablets, 250mg, containing a Paragraph IV certification.
- June 2020 – The U.S. FDA announced the approval of Phesgo—a combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body and for treatment of adult patients with early HER2-positive breast cancer. The patients undergoing this therapy should be selected based on an FDA-approved companion diagnostic test.
Report Scope
| Report Coverage | Details |
| Forecast Period | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR | 13.1% |
| 2027 Value Projection | USD 55.27 Billion |
| Base Year | 2020 |
| Market Size in 2019 | USD 21.58 Billion |
| Historical Data for | 2017 to 2019 |
| No. of Pages | 175 |
Regional Insights-
North America to Remain at the Forefront Stoked by Rising Awareness Programs
Regionally, North America procured USD 10.34 billion in 2019 in terms of revenue. The rising prevalence of breast cancer, presence of numerous providers of breast cancer therapeutics, and the surging awareness of this condition are expected to augment growth in this region. The American Cancer Society, for instance, declared that the U.S. is set to experience around 276,480 new cases of invasive breast cancer in 2020.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163
Europe, on the other hand, is likely to retain its second position fueled by the high demand for advanced and sophisticated breast cancer therapeutics. In Asia Pacific, the market would grow rapidly because of the increasing healthcare expenditure. Lastly, the Middle East & Africa and Latin America are anticipated to show robust growth on account of the rising patient population in both regions.
Drivers & Restraints-
Increasing Development of State-of-the-art Products to Favor Growth
Nowadays, several renowned companies are constantly launching new breast cancer therapeutics worldwide. Most of these drugs are meant for the treatment of those types of breast cancers that were previously untreatable or the available drugs were not successful for providing positive outcomes. These factors are expected to accelerate the breast cancer therapeutics market growth in the forthcoming years. However, certain severe reactions can come up while undergoing breast cancer therapeutics, such as targeted therapies. Patients can suffer from nausea, fatigues, rashes, gastrointestinal problems, or high blood pressure. These may hinder growth.
COVID-19 Pandemic to Affect Growth Moderately as Cancer Requires Immediate Attention
The COVID-19 pandemic has moderately affected the growth of the breast cancer therapeutics industry worldwide as cancer is considered to be an essential condition that requires immediate medical attention. But, in some regions, there were a few postponements or cancellations of these procedures to prevent physical contact.
Quick Buy - Breast Cancer Therapeutics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100163
This Report Answers the Following Questions:
- Which organizations are likely to generate the largest revenues?
- What are the historical and predicted sizes of the global market?
- Will the COVID-19 pandemic affect the market in the near future?
- What are the strategies followed by companies to generate more sales?
Segment-
Hormonal Therapy Segment to Register Lower Growth in Forthcoming Years
Based on therapy, the hormonal therapy segment generated 8.3% in terms of the breast cancer therapeutics market share in 2019. It is likely to exhibit lower growth in the coming years on account of the rising availability of their generic equivalents.
| Segmentation | By Therapy
|
By Cancer Type
| |
By Distribution Channel
|
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/breast-cancer-therapeutics-market-100163
Competitive Landscape-
Key Players Aim to Gain Fast Track Approvals to Compete with Their Rivals
The global market for breast cancer therapeutics houses a large number of companies that are nowadays striving to gain fast track approvals from government healthcare agencies to distribute and market their products. Some of the others are focusing on developing unique breast cancer therapeutics to cater to the unmet demand. Below are the two latest industry developments:
- September 2020: Lupin introduced Lapatinib Tablets, 250 mg, after its partner Natco Pharma received approval from the USFDA. These will be used to treat patients suffering from metastatic or advanced breast cancer.
- November 2019: Daiichi Sankyo Company and AstraZeneca declared that their HER2-directed antibody-drug conjugate named Enhertu was approved by the USFDA. It is meant for the treatment of adult patients living with metastatic or unresectable HER2-positive breast cancer.
A list of all the renowned breast cancer therapeutics providers present in the global market:
- Genentech (F. Hoffmann-La Roche Ltd) (South San Francisco, U.S.)
- Eli Lilly and Company (Indianapolis, U.S.)
- Novartis AG (Basel, Switzerland)
- AstraZeneca (Cambridge, U.K.)
- Pfizer Inc. (New York City, U.S.)
- Sanofi (Paris, France)
- Eisai Co. Ltd. (Tokyo, Japan)
- Kyowa Kirin (Tokyo, Japan)
- Bristol Myers Squibb (Celgene Corporation) (New York City, U.S.)
- Merck & Co., Inc. (Kenilworth, U.S.)
- Other Players
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/breast-cancer-therapeutics-market-100163
Table of Content from Breast Cancer Therapeutics Market:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Breast Cancer, By Key Countries/Regions, 2019
- Regulatory Scenario by Key Regions
- Overview of Current Advances in R&D for Breast Cancer Therapeutics
- Key Industry Developments
- New Product Launches
- Global Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Market Analysis, Insights and Forecast – By Cancer Type
- Hormone Receptor
- HER+
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis – By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Market Analysis – By Cancer Type
- Hormone Receptor
- HER+
- Market Analysis – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis – By Country
- U.S.
- Canada
Continued...
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
